Veloxis Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
HORSHOLM, Denmark, Feb. 29, 2012 /PRNewswire/ -- Edward Koval, senior vice president, business development, of Veloxis Pharmaceuticals A/S, will present at the Cowen and Company 32nd Annual Health Care Conference at 2:10 p.m. EST, Monday, March 5, at the Boston Marriott Copley Place in Boston. Mr. Koval will present an overview of the company and discuss top-line Phase 3 results of LCP-Tacro™, Veloxis' candidate to prevent organ transplant rejection.
About Veloxis Pharmaceuticals A/S
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability -- at low-scale up costs -- not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development.
For further information, please visit www.veloxis.com.
For U.S. investor and media contacts:
John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations
Veloxis Pharmaceuticals A/S
SOURCE Veloxis Pharmaceuticals A/S
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.